Haisco Pharmaceutical Group

Diversified pharma

002653 · SZSE · China

Public Market Listing

002653SZSE

SZSE primary exchange listing

Live quotes, historical charts, and market capitalization for Haisco Pharmaceutical Group are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(8 total)
8Total Assets
0Approved
5Phase 3 / Filed
3Phase 1–2 / Early
10Diseases
Quick filter:
Showing 8 of 8 assets
Target & Modality
Phase 3
Kappa-opioid receptor (agonist, peripherally restricted)Peptide
Chronic Kidney Disease
Phase 3
DPP-4Small molecule
Type 2 Diabetes
Phase 3
α2δ-1 subunit of voltage-gated calcium channelsSmall molecule
Diabetic Peripheral Neuropathic Pain
Phase 3
Phosphodiesterase 3 and Phosphodiesterase 4 (PDE3/PDE4)Small molecule
Chronic Obstructive Pulmonary Disease
Phase 3
PDE4BSmall molecule
Atopic DermatitisPsoriasisIdiopathic Pulmonary Fibrosis
Phase 2
IL-23 receptorPeptide
Inflammatory Bowel DiseasePsoriasis
Ulcerative Colitis
Phase 1
EGFRSmall molecule
Non-Small Cell Lung Cancer
Phase 1
PRMT5Small molecule
Non-Small Cell Lung CancerPancreatic Ductal Adenocarcinoma

Upcoming events

(11 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
HSK47388Phase 2Plaque Psoriasis
Est. primary completion 2026-12-20 · NCT07158268 · CT.gov ↗
What to watch
2027 (8)
March 2027 (1)
HSK44459Phase 1/2Psoriasis
Est. primary completion 2027-03 · NCT07623486 · CT.gov ↗
What to watch
June 2027 (1)
HSK39004Phase 3COPD (Chronic Obstructive Pulmonary Disease)
Est. primary completion 2027-06-11 · NCT07658339 · CT.gov ↗
What to watch
July 2027 (3)
HSK44459Phase 2Bechet's Disease
Est. primary completion 2027-07 · NCT07070739 · CT.gov ↗
What to watch
HSK39004Phase 2Chronic Obstructive Lung Disease (COLD)
Est. primary completion 2027-07 · NCT07425210 · CT.gov ↗
What to watch
CrisugabalinPhase 3Central Neuropathic Pain
Est. primary completion 2027-07-30 · NCT06422117 · CT.gov ↗
What to watch
September 2027 (1)
HSK39004Phase 3COPD (Chronic Obstructive Pulmonary Disease)
Est. primary completion 2027-09-30 · NCT07583849 · CT.gov ↗
What to watch
October 2027 (1)
HSK47388Phase 2Ulcerative Colitis (UC)
Est. primary completion 2027-10-15 · NCT07335055 · CT.gov ↗
What to watch
December 2027 (1)
HSK39004Phase 3COPD (Chronic Obstructive Pulmonary Disease)
Est. primary completion 2027-12-24 · NCT07634367 · CT.gov ↗
What to watch
2028 (2)
April 2028 (1)
HSK44459Phase 3IPF
Est. primary completion 2028-04-05 · NCT07519070 · CT.gov ↗
What to watch
December 2028 (1)
HSK44459Phase 3Progressive Pulmonary Fibrosis
Est. primary completion 2028-12-30 · NCT07503587 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

October 2026PresentationHSK41959Phase 1 data at ESMO 2026: ORR 25.5% in 55 evaluable patients at 400 mg and above
8 September 2026Topline resultHSK39004Phase 2b HSK39004-T1-202 (NCT07108699) met its primary endpoint
AirNexis Therapeutics · Source ↗

Financial reports

Quarterly & interim (15)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q1$231M$33M$267M—report ↗
View 14 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-Q3$461M$76M$197M—report ↗
2025-H1$276M$47M$203M—report ↗
2024-Q3$384M$53M$115M—report ↗
2024-H1$234M$30M$148M—report ↗
2024-Q1$105M$12M$201M—report ↗
2023-Q3$330M$38M$121M—report ↗
2023-H1$198M$30M$166M—report ↗
2023-Q1$91M$13M$163M—report ↗
2022-Q3$306M$34M$80M—report ↗
2022-H1$193M$28M$159M—report ↗
2022-Q1$89M$11M$95M—report ↗
2021-Q3$295M$44M$83M—report ↗
2021-H1$197M$26M$128M—report ↗
2021-Q1$112M$14M$150M—report ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$611M$112M$198M—report ↗

Haisco Pharmaceutical Group reported revenue of $610.87M, up 17.9% YoY, R&D spend of $111.97M, up 28.9% YoY, and cash and equivalents of $198.03M for fiscal year 2025.

Figures only: this period's report disclosed no narrative text

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$518M$87M$145M—report ↗
2023-FY$475M$73M$164M—report ↗
2022-FY$449M$67M$111M—report ↗
2021-FY$430M$67M$90M—report ↗